Majamil Prolongatum (Diclofenac Sodium)

Majamil Prolongatum, a diclofenac‑based NSAID, acts on inflammatory pathways to alleviate pain and swelling.

• Mild to moderate pain: provides analgesic relief in acute or chronic pain conditions.
• Inflammatory musculoskeletal conditions: reduces joint inflammation and improves mobility.
• Osteoarthritis: lessens joint pain and stiffness associated with cartilage degeneration.
• Rheumatoid arthritis: helps control inflammatory attacks and joint discomfort.
• Post‑operative pain: mitigates surgical site pain and associated inflammation.

• Diclofenac sodium reversibly inhibits cyclooxygenase‑1 (COX‑1) and cyclooxygenase‑2 (COX‑2) enzymes, decreasing the conversion of arachidonic acid to prostaglandins. The reduced prostaglandin synthesis leads to diminished inflammatory mediator levels, thereby lowering pain perception, fever, and swelling at the site of tissue injury.

Adverse reactions may occur with any NSAID therapy. Patients should be aware of both frequent and less common events.

Common Side Effects

• Gastrointestinal discomfort: nausea, dyspepsia, or abdominal pain.
• Headache: mild to moderate intensity.
• Dizziness or vertigo.
• Skin rash or mild pruritus.
• Elevated liver enzymes detected in routine labs.

Serious or Rare Side Effects

• Gastrointestinal ulceration or bleeding, which may be life‑threatening.
• Hepatotoxicity: severe liver injury presenting with jaundice.
• Renal impairment: acute kidney injury or worsening chronic kidney disease.
• Severe hypersensitivity reactions, including Stevens‑Johnson syndrome.

Before initiating therapy, clinicians should evaluate patient history and comorbidities.

• Hypersensitivity: avoid in patients with known allergy to diclofenac or other NSAIDs.
• Cardiovascular risk: use cautiously in individuals with hypertension, heart failure, or prior thrombotic events.
• Gastrointestinal history: assess for prior ulcer disease or bleeding; consider gastro‑protective agents.
• Renal function: monitor serum creatinine in patients with existing kidney disease.
• Pregnancy and lactation: evaluate risk‑benefit; generally contraindicated in the third trimester.
• Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Diclofenac may alter the pharmacokinetics or pharmacodynamics of several medicines.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin): increased risk of serious bleeding.
• Lithium: diclofenac can raise serum lithium concentrations, leading to toxicity.
• Methotrexate: reduced clearance may cause heightened toxicity.
• SSRIs or SNRIs: combined use raises bleeding potential.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: may impair renal function, especially in volume‑depleted patients.
• Diuretics: concurrent use can exacerbate renal insufficiency.
• Cyclosporine: increased risk of nephrotoxicity.